stocks logo

PALI

Palisade Bio Inc
$
1.240
+0.08(6.897%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.400
Open
1.200
VWAP
--
Vol
1.67M
Mkt Cap
5.95M
Low
1.150
Amount
--
EV/EBITDA(TTM)
--
Total Shares
936.40K
EV
-1.67M
EV/OCF(TTM)
--
P/S(TTM)
--
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Show More
1 Analyst Rating
up Image
61.29% Upside
Wall Street analysts forecast PALI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PALI is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image
61.29% Upside
Current: 1.240
sliders
Low
2.00
Averages
2.00
High
2.00
Brookline Capital
Kumaraguru Raja
Strong Buy
Initiates
$38
2024-11-20
Reason
Brookline initiated coverage of Palisade Bio with a Buy rating and $38 price target. Palisade Bio is advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, the analyst noted.
Maxim Group
Naz Rahman
Strong Buy
Maintains
$23 → $8
2024-11-13
Reason

Valuation Metrics

The current forward P/E ratio for Palisade Bio Inc (PALI.O) is -0.87, compared to its 5-year average forward P/E of -0.98. For a more detailed relative valuation and DCF analysis to assess Palisade Bio Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.98
Current PE
-0.87
Overvalued PE
-0.24
Undervalued PE
-1.72

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.36
Current PS
0.00
Overvalued PS
32.13
Undervalued PS
-13.42

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-37.11%
-2.31M
Operating Profit
FY2025Q1
YoY :
-36.77%
-2.23M
Net Income after Tax
FY2025Q1
YoY :
-89.76%
-0.47
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PALI News & Events

Events Timeline

2025-07-09 (ET)
2025-07-09
08:46:56
Palisade Bio appoints to its Board of Directors
select
2025-05-27 (ET)
2025-05-27
08:44:24
Palisade Bio files to sell 13.14M shares of common stock, warrants
select
2025-05-27
08:35:41
Palisade Bio reports Phase 1a results for PALI-2108
select
Sign Up For More Events

News

9.5
07-24Benzinga
Why Alphabet Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
8.5
07-24Newsfilter
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
1.0
07-22Newsfilter
Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
Sign Up For More News

FAQ

arrow icon

What is Palisade Bio Inc (PALI) stock price today?

The current price of PALI is 1.24 USD — it has increased 6.9 % in the last trading day.

arrow icon

What is Palisade Bio Inc (PALI)'s business?

arrow icon

What is the price predicton of PALI Stock?

arrow icon

What is Palisade Bio Inc (PALI)'s revenue for the last quarter?

arrow icon

What is Palisade Bio Inc (PALI)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Palisade Bio Inc (PALI)'s fundamentals?

arrow icon

How many employees does Palisade Bio Inc (PALI). have?

arrow icon

What is Palisade Bio Inc (PALI) market cap?